Company: PMVP
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001140361-25-015610
Chunk: 18

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 18
---
2022. She also serves on the board of directors of Sionna Therapeutics (Nasdaq: SION), a clinical-stage biopharmaceutical company, Spyre Therapeutics Inc. (Nasdaq: SYRE), a biotechnology company, and served on the board of directors of Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company until its acquisition by Coherus BioSciences in September 2023. Prior to joining Arena Pharmaceuticals, Ms. Stelzer was the Chief Financial Officer at Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharma technology platform company, from June 2015 to March 2020. Prior to joining Halozyme Therapeutics, Ms. Stelzer held senior management roles at Shire Plc (acquired by Takeda), including Senior Vice President of Finance, Division Chief Financial Officer for the Regenerative Medicine Division and Head of Investor Relations. Previously, she also worked at Amgen for 15 years, serving in positions of increasing responsibility in the areas of Finance, Treasury, Global Accounting and International/Emerging Markets. Ms. Stelzer received her B.S. in Accounting from Arizona State University and her M.B.A. from University of California, Los Angeles, Anderson School of Management. We believe that Ms. Stelzer is qualified to serve on our board of directors because of her extensive executive and financial experience at multiple public companies in the biopharmaceutical and biotechnology industries. Board of Directors Diversity Matrix

|                                     |     |   As of (Date) 
 March 31, 2024 |     |      |     |        |     |          |     | March 31, 2025 |     |      |     |        |     |          |
|:------------------------------------|:----|---------------:|:----|-----:|:----|-------:|:----|---------:|:----|---------------:|:----|-----:|:----|-------:|:----|---------:|
| Total Number of Directors           |     |              7 |     |      |     |        |     |          |     |              7 |     |      |     |        |     |          |
| Part I: Gender Identity             |     |         Female |     | Male |     |   Non- 
 Binary |     |  Did Not 
 Disclose 
   Gender |     |